EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure

Paul J Clark, Patricia C Valery iD, Simone I Strasser, Martin Weltman, Alex Thompson, Miriam T Levy iD, Barbara Leggett, Amany Zekry, Y Julian Rong, Marie Sinclair iD, Jacob George iD, William Sievert und 5 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70219 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Paul J Clark und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Princess Alexandra and Mater Hospitals, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, …. Hauptthemen laut MEDLINE: Hepatitis C, Antiviral Agents, Mortality. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Commonwealth Department of Health, Merck, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Cure of hepatitis C virus (HCV) infection decreases liver‐ and all‐cause mortality. However, the risk of early mortality after HCV cure remains. We examined factors associated with cause‐specific mortality after direct‐acting antiviral (DAA) therapy.

Methods

DAA‐treated adults (recruited 2016–2021) were followed up to September 2023. Medication, health‐service use, and deaths were obtained from population databases. The primary outcome was all‐cause and cause‐specific mortality.

Results

Among 3619 patients (average 52.0 years (SD = 10.5), 66.0% male, 33.6% with cirrhosis) followed for a median of 6.8 years (IQR 5.5–7.4), 423 (11.7%) died (40.6% due to liver disease, 13.2% self‐harm/accidental poisoning and 12.3% respiratory disease/lung cancer). Cirrhosis (adjusted hazard ratio (adj‐HR) = 14.51, 95% CI 6.87–30.64), FIB4 > 3.25 (adj‐HR = 4.22, 95% CI 2.63–6.80), nonsustained virological response (SVR) (adj‐HR = 3.94, 95% CI 2.64–5.88) and age ≥ 60 years (adj‐HR = 1.88, 95% CI 1.32–2.69) increased liver‐related mortality risk. Mortality was threefold higher in non‐SVR (32.4% of 210 patients vs. 10.2% of 2894 with SVR, p < 0.001). Non‐SVR increased risk of liver mortality (adj‐HR = 4.30, 95% CI 2.90–6.37). Mental health medication use (adj‐HR = 2.82, 95% CI 1.40–5.67), loss to clinical follow‐up (adj‐HR = 2.61, 95% CI 1.31–5.21) and injection drug use/opioid replacement therapy (adj‐HR = 2.26, 95% CI 1.23–4.14) increased risk of self‐harm/accidental poisoning ‐related mortality . Age ≥ 60 years and diabetes increased mortality risk from other extrahepatic cancer (adj‐HR = 2.68, 95% CI 1.31–5.51 and adj‐HR = 2.57, 95% CI 1.15–5.72) and cardiovascular disease (adj‐HR = 2.71, 95% CI 1.06–4.19 and adj‐HR = 2.28, 95% CI 1.03–5.05).

Conclusions

Liver‐related death drives mortality for cirrhotic patients. Curing HCV remains critical. Holistic HCV care, with attention to mental health illnesses in younger patients, metabolic comorbidities, and better cancer screening for older patients may reduce excess mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CAntiviral AgentsMortalityHumansMaleFemaleAdultMiddle AgedLiver DiseasesLung NeoplasmsPoisoningSuicide, CompletedRisk FactorsCardiovascular DiseasesProspective StudiesRegistriesAustraliaSurvival Analysis

Stichwörter der Autor:innen

cirrhosisdirect‐acting antiviralhepatocellular carcinomaliver diseaseliver fibrosis

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Princess Alexandra and Mater Hospitals, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • QIMR Berghofer Medical Research Institute, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.
  • Hepatology Services, Nepean Hospital, Penrith, New South Wales, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Gastroenterology and Liver, Liverpool Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Patricia C Valery, Miriam T Levy, Marie Sinclair, Jacob George, Stuart K Roberts

Förderung

  • Commonwealth Department of Health
  • Merck
  • AbbVie
  • Australian Government
  • Gilead Sciences

Zitieren

APA

Clark, P. J., Valery, P. C., Strasser, S. I., Weltman, M., Thompson, A., Levy, M. T., Leggett, B., Zekry, A., Rong, Y. J., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Wade, A., Cheng, W., & Roberts, S. K. (2025). Surviving Hepatitis C—Understanding Death and Survival Beyond Cure. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70219

Vancouver

Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson A, Levy MT, et al. Surviving Hepatitis C—Understanding Death and Survival Beyond Cure. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70219

BibTeX
@article{Clark2025,
  author = {Clark, Paul J and Valery, Patricia C and Strasser, Simone I and Weltman, Martin and Thompson, Alex and Levy, Miriam T and Leggett, Barbara and Zekry, Amany and Rong, Y Julian and Sinclair, Marie and George, Jacob and Sievert, William and MacQuillan, Gerry and Tse, Edmund and Wade, Amanda and Cheng, Wendy and Roberts, Stuart K},
  title = {Surviving Hepatitis C—Understanding Death and Survival Beyond Cure},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70219}
}
Kostenlos starten →